Instructions for Symbicort Rapihaler (budesonide, formoterol) aerosol for inhalation 120 doses
English product name
Symbicort Rapihaler
Release Form Symbicort Rapihaler
Aerosol d/inhalation dosed 80 ug+4.5 ug/1 dose: 120 dose inhaler
Aerosol d/inhalation dosed 160 ug+4.5 ug/1 dose: 120 dose inhaler
Description Symbicort Rapihaler:
Aerosol for inhalation dosed; Contents of the cylinder are a solid white residue free from visible inclusion, formed after evaporation of the propellent.
1 dose*
budesonide micronized 80 ug
Fumarat Fumarate mimicized 4.5 ug
Auxiliary substances: k25 - 0.75 ug, 1000 - 223.8 ug, apafluran 227 - up to 74.6 mg.
8 ml (120 doses) - Inhalers** (1) - packs made of aluminum laminated foil (1) with desicante - packs of cardboard with first autopsy control.
* For the quality control of a drug, the term "dose" corresponds to one release of the drug. Therapeutic dose is 2 releases of the drug.
** Inhaler: A cylinder located inside a red spraying device with a white uniform and a gray dose counter; A gray protective cap is attached to the spraying device by a latch. Primary packaging: The contents are in a metal cylinder equipped with a plastic dosing cap. There is no corrosion and defects on the outer and inner surfaces of the cylinder and valve.
ATX codes
R03AK07 Formoterol and budesonid
Pharmaceutical / Group Membership Symbicort Rapihaler
Combination broncholitic medication - selective beta<SUB>2</SUB>-adrenomymetic + local glucorticosteroid
Valid substance
besonide
formoterol fumara digirate
Pharmaceutical group
Bronchylatitis combined (beta2-adrenomymetic selective+glucorticosteroid local)
Retention Conditions Symbicort Rapihaler
It should be kept in a place that is not accessible to children at temperatures not exceeding 30°C.
Best before date
Expiration date is two years; After the first opening of the package - 3 months. Do not apply after the expiry date specified on the package.
Indications Symbicort Rapihaler:
- bronchial asthma,
- under-controlled reception of inhalation HCS in small doses and CB2-adreno short-action stimulants,
- if appropriate combined therapy for inhalation HCS and bs2-adreno-stimulants of long-term effect;
- symptomatic therapy for patients with HOBL with post-bronchodilate OHF1 <70% of due and accentuated in anamenza,
- despite regular treatment with bronchodilatators.
Method of application, course and dosage Symbicort Rapihaler:
For inhalation application.
Simbikort® Rapihaler comes directly into the lungs after inhalation, so the patient must be trained to use the inhaler properly (see the section "Instructions for the use of Simbikort® Rapihaler").
The patient should be informed of the need to use Simbikort® Rapihaler regularly, i.e. to continue to receive even if there are no symptoms of the disease in order to achieve the greatest therapeutic effect.
Bronchial asthma Rapihaler
The dose of Simbikort® Rapichaler should be regularly monitored by a doctor who adjusts it individually according to the severity of the disease according to the recommendations in force. Initial doses are selected for effective symptom control. After the desired clinical effect has been achieved, the dose should be gradually reduced to a minimum dose, which allows optimal control of the symptoms of bronchial asthma. Thus, afterwards it is possible to switch to treatment only inhalation HCS. When the treatment with Simbikort® is terminated, it is recommended to gradually reduce the dose.
In case of severe bronchial asthma, regular medical supervision is necessary, as life-threatening situations may arise.
kidney damage
There is no data on the use of Simbikort® Rapichaler in patients with kidney disorders.
liver function violation
There is no data on the use of Simbikort® Rapihaler in patients with liver disorders.
The deposition of budesonide and Formoterol is mainly through metabolism in the liver, so exposure can increase in patients with severe liver disease. Such patients must be closely monitored.
Implementation Conditions
The drug is released by prescription.
Application to older patients
There is no need to correct the dose of older patients.
Child use
The use of the medication in children under 6 years of age is not shown.
The drug with a dosage of 160 ug + 4.5 ug/dose is contraindicated at the age of 12 years.
- Nosology Symbicort Turbuhaler (ICD codes)
- J44
- Another chronic obstructive pulmonary disease
- J45
- Astma
